ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 96.7% in October

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 24,000 shares, a decrease of 96.7% from the October 15th total of 717,700 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average daily volume of 316,200 shares, the short-interest ratio is presently 0.1 days.

ENDRA Life Sciences Stock Down 7.7 %

Shares of NASDAQ NDRA traded down $0.44 during midday trading on Thursday, reaching $5.29. 25,931 shares of the company were exchanged, compared to its average volume of 97,688. ENDRA Life Sciences has a one year low of $5.23 and a one year high of $4,882.50. The stock has a market cap of $2.61 million, a P/E ratio of 0.00 and a beta of 0.74. The stock’s 50-day moving average price is $8.15 and its 200-day moving average price is $7,616.00.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($140.00) EPS for the quarter, missing the consensus estimate of ($122.50) by ($17.50). On average, equities research analysts anticipate that ENDRA Life Sciences will post -387.41 EPS for the current year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.